Morgan Stanley raised the firm’s price target on Synovus (SNV) to $61 from $58 and keeps an Equal Weight rating on the shares. The firm is increasing its 2025 and 2026 EPS forecasts 9% and 6%, respectively, driven by better credit performance and revenues after a “strong” Q2 beat, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNV:
- Synovus Financial Outlook: Balancing Growth Potential with Cost Management Concerns
- Synovus price target raised to $65 from $55 at RBC Capital
- Synovus’s Strong Financial Performance and Strategic Positioning Drive Buy Rating
- Synovus upgraded to Outperform from Market Perform at Keefe Bruyette
- Synovus upgraded to Outperform from Market Perform at Raymond James